Literature DB >> 12920574

Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians.

Yasmine L Konheim1, Johanna K Wolford.   

Abstract

Recent studies have suggested that prostaglandin-endoperoxide synthase-2 (PTGS2), also known as cyclo-oxygenase 2, plays an etiological role in the development of type 2 diabetes mellitus (T2DM). PTGS2 generates prostaglandins, which negatively modulate glucose-stimulated insulin secretion, and functions as a mediator of the inflammatory response, which is associated with decreased insulin sensitivity. Moreover, the gene encoding this enzyme, PTGS2, is located on 1q25.2, a region that has been linked with early onset T2DM in Pima Indians. To determine the possible role played by PTGS2 in modulating susceptibility to T2DM, we screened approximately 7.0 kb of the gene, corresponding to the promoter, coding sequence, and flanking exon-intron boundaries, and identified five variants, including three single nucleotide polymorphisms (SNPs) in the promoter, one intronic SNP, and one in the 3' untranslated region. With the exception of one rare promoter SNP (minor allele frequency <0.03), all SNPs were typed in approximately 1000 Pima Indians. The range of frequencies for the more common alleles was 0.65-0.88, and we found substantial linkage disequilibrium between all PTGS2 SNP pairs (D'>/=0.95). Variant alleles at two markers, rs20417 and rs2066826, which are located in the promoter and intron 6, respectively, were in strong linkage disequilibrium with each other (D'=0.97) and were associated with a higher prevalence of T2DM. For marker rs20417, individuals with the variant CC genotype had a 30% higher T2DM prevalence compared with subjects with the GG genotype (odds ratio=1.6 per copy of C allele; P=0.01). The variant C allele of rs20417 has been associated with decreased PTGS2 promoter activity, thereby suggesting a possible biological consequence attributable to this polymorphism. These findings indicate that genetic variants in PTGS2 may play a role in mediating susceptibility to T2DM in Pima Indians and are consistent with the hypothesis that chronic inflammation may contribute to the development of T2DM in some individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920574     DOI: 10.1007/s00439-003-1000-y

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

1.  Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.

Authors:  Q Xu; Y S Ji; J F Schmedtje
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

2.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Authors:  J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study.

Authors:  M I Schmidt; B B Duncan; A R Sharrett; G Lindberg; P J Savage; S Offenbacher; M I Azambuja; R P Tracy; G Heiss
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

5.  High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes.

Authors:  Barbora Vozarova; Christian Weyer; Robert S Lindsay; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

6.  Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

Authors:  Anastasia Papafili; Michael R Hill; David J Brull; Robin J McAnulty; Richard P Marshall; Steve E Humphries; Geoffrey J Laurent
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

7.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

8.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Inhibition of in vivo insulin secretion by prostaglandin E1.

Authors:  R P Robertson; D J Gavareski; D Porte; E L Bierman
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

View more
  20 in total

Review 1.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

2.  Systems genetics of metabolism: the use of the BXD murine reference panel for multiscalar integration of traits.

Authors:  Pénélope A Andreux; Evan G Williams; Hana Koutnikova; Riekelt H Houtkooper; Marie-France Champy; Hugues Henry; Kristina Schoonjans; Robert W Williams; Johan Auwerx
Journal:  Cell       Date:  2012-08-30       Impact factor: 41.582

3.  Study on the association of COX-2 genetic polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu province in China.

Authors:  Zhu Ke-Xiang; Li Yu-Min; Li Xun; Zhou Wen-Ce; Shan Yong; Liu Tao
Journal:  Mol Biol Rep       Date:  2010-04-04       Impact factor: 2.316

Review 4.  Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Authors:  Bethany A Carboneau; Richard M Breyer; Maureen Gannon
Journal:  J Cell Commun Signal       Date:  2017-01-28       Impact factor: 5.782

5.  CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2.

Authors:  Ondrej Kuda; Christopher M Jenkins; James R Skinner; Sung Ho Moon; Xiong Su; Richard W Gross; Nada A Abumrad
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

6.  Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.

Authors:  Yi-Cheng Chang; Pi-Hua Liu; Yun-Chih Tsai; Yen-Feng Chiu; Shyang-Rong Shih; Low-Tone Ho; Wen-Jane Lee; Chieh-Hua Lu; Thomas Quertermous; J David Curb; Wei-Jei Lee; Po-Chu Lee; You-Han He; Jih-I Yeh; Juey-Jen Hwang; Shu-Huei Tsai; Lee-Ming Chuang
Journal:  J Mol Med (Berl)       Date:  2012-04-15       Impact factor: 4.599

7.  Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner.

Authors:  E Alpert; A Gruzman; B Lardi-Studler; G Cohen; R Reich; S Sasson
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

8.  PharmGKB summary: very important pharmacogene information for PTGS2.

Authors:  Caroline F Thorn; Tilo Grosser; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

9.  Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.

Authors:  Megan E Rudock; Yongmei Liu; Julie T Ziegler; Stewart G Allen; Allison B Lehtinen; Barry I Freedman; J Jeffrey Carr; Carl D Langefeld; Donald W Bowden
Journal:  Atherosclerosis       Date:  2008-07-26       Impact factor: 5.162

10.  Maternal High-Fat Diet Exposure During Gestation and Lactation Affects Intestinal Development in Suckling Rats.

Authors:  Monika Słupecka-Ziemilska; Paulina Grzesiak; Paweł Kowalczyk; Piotr Wychowański; Jarosław Woliński
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.